Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics Inc
(NQ:
PTGX
)
35.55
-0.16 (-0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Protagonist Therapeutics Inc
< Previous
1
2
Next >
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
June 13, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
May 31, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
May 14, 2024
Via
ACCESSWIRE
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
May 07, 2024
Via
ACCESSWIRE
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
March 26, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
Via
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 27, 2024
Via
ACCESSWIRE
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024
From
Turnstone Biologics Corp.
Via
GlobeNewswire
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
March 18, 2024
Via
ACCESSWIRE
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
March 11, 2024
Via
ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 21, 2024
Via
ACCESSWIRE
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
Via
ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
October 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
February 20, 2024
Via
ACCESSWIRE
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
February 07, 2024
Via
ACCESSWIRE
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
January 31, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
January 29, 2024
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
Via
ACCESSWIRE
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
December 13, 2023
Via
ACCESSWIRE
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
December 12, 2023
Via
ACCESSWIRE
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
November 27, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
November 16, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
November 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
November 02, 2023
Via
ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
November 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
November 01, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
October 30, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
October 03, 2023
Via
ACCESSWIRE
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
September 22, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,...
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.